{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"11"}],"units":"Participants"}],"description":"Evaluate safety at the dose(s) used to assess imaging feasibility and select the dose(s) and imaging schedule(s) post dose that are safe and provide optimal imaging of solid tumors and metastatic lymph nodes; the dose and time post dose chosen for the detection of primary tumors and metastatic lymph nodes could be the same or different.","groups":[{"description":"Patients were administered a single IV infusion of ONM-100 at a dose of 1 mg/kg.","id":"OG000","title":"Part 1, Cohort A"},{"description":"Patients were administered a single IV infusion of OMN-100 at a dose of 3 mg/kg.","id":"OG001","title":"Part 1, Cohort B"},{"description":"Patients were administered a single IV infusion of OMN-100 at a dose of 2 mg/kg.","id":"OG002","title":"Part 1, Cohort E"},{"description":"Patients were administered a single IV infusion of ONM-100 at a dose of 3 mg/kg.","id":"OG003","title":"Part 2, Group 2"},{"description":"Patients were administered a single IV infusion of ONM-100 at a dose of 1 mg/kg.","id":"OG004","title":"Part 2, Group 3"},{"description":"Patients were administered a single IV infusion of ONM-100 at a dose of 1 mg/kg.","id":"OG005","title":"Part 3"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"28 days","title":"Incidence Rate of All Treatment-emergent Adverse Events (TEAEs) From Time of ONM-100 Administration Through Day 28","type":"PRIMARY","unitOfMeasure":"Participants"}